Evusheld may not prevent COVID-19 in immunocompromised individuals exposed to the XBB.1.5 omicron subvariant, because the treatment has failed to neutralize similar subvariants, the Food and Drug Administration announced Friday. While it awaits additional data to verify this, FDA recommends health care providers inform patients about this risk, and advise them to test for COVID-19 and seek medical attention if they develop symptoms. XBB.1.5 currently accounts for about 28% of SARS-CoV-2 variants circulating in the U.S.

In other news, the FDA Friday approved through its accelerated pathway a new treatment for Alzheimer’s disease (Leqembi), the second in a new category of Alzheimer’s medications that target the underlying disease process.

Related News Articles

Headline
The Food and Drug Administration last week removed the requirement for a positive COVID-19 test result to prescribe Paxlovid to certain adult and…
Headline
The House last night voted 220-210 to pass legislation (H.R.382) that would immediately terminate the COVID-19 public health emergency, and 227-203 to pass…
Headline
The AHA is offering a new set of social messages and assets for February to encourage the public to get vaccinated and boosted against COVID-19. The new…
Headline
A Food and Drug Administration advisory committee unanimously voted today to recommend harmonizing the composition of all COVID-19 vaccine primary series and…
Headline
In a study released today by the Centers for Disease Control and Prevention, a single bivalent COVID-19 vaccine booster provided additional protection against…
Headline
A Food and Drug Administration advisory committee is scheduled to vote Thursday on whether to simplify current COVID-19 vaccine use so that all primary series…